Jason  Throne net worth and biography

Jason Throne Biography and Net Worth

insider of IDEAYA Biosciences

Jason has over 20 years of legal experience representing both public and private life sciences companies. He joined IDEAYA Biosciences as Vice President, General Counsel in October 2019. Prior to joining IDEAYA Biosciences, Jason served as Vice President, General Counsel of NeoTract, Inc., a urology medical device company, until its acquisition by Teleflex Incorporated. Prior to NeoTract, Jason held various roles, including Associate General Counsel, Corporate & Compliance Officer, at Thoratec Corporation (NASDAQ: THOR), a cardiology medical device company, which was acquired by St. Jude Medical. Previously, Jason was an associate at the law firm of Cooley Godward LLP, representing both private and public companies on corporate matters, and a senior audit accountant at the accounting firm of Deloitte & Touche LLP.

Jason earned a J.D. from the University of Virginia School of Law and a B.S. in Business from the University of Colorado.

What is Jason Throne's net worth?

The estimated net worth of Jason Throne is at least $824,660.85 as of September 1st, 2023. Mr. Throne owns 32,531 shares of IDEAYA Biosciences stock worth more than $824,661 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Throne may own. Additionally, Mr. Throne receives an annual salary of $598,800.00 as insider at IDEAYA Biosciences. Learn More about Jason Throne's net worth.

How old is Jason Throne?

Mr. Throne is currently 52 years old. There are 4 older executives and no younger executives at IDEAYA Biosciences. The oldest executive at IDEAYA Biosciences is Dr. Michael A. White Ph.D., Chief Scientific Officer, who is 58 years old. Learn More on Jason Throne's age.

What is Jason Throne's salary?

As the insider of IDEAYA Biosciences, Inc., Mr. Throne earns $598,800.00 per year. There are 3 executives that earn more than Mr. Throne. The highest earning executive at IDEAYA Biosciences is Mr. Yujiro S. Hata, President, CEO & Director, who commands a salary of $912,000.00 per year. Learn More on Jason Throne's salary.

How do I contact Jason Throne?

The corporate mailing address for Mr. Throne and other IDEAYA Biosciences executives is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. IDEAYA Biosciences can also be reached via phone at (650) 443-6209 and via email at [email protected]. Learn More on Jason Throne's contact information.

Has Jason Throne been buying or selling shares of IDEAYA Biosciences?

Jason Throne has not been actively trading shares of IDEAYA Biosciences during the last quarter. Most recently, Jason Throne sold 5,163 shares of the business's stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $30.09, for a transaction totalling $155,354.67. Learn More on Jason Throne's trading history.

Who are IDEAYA Biosciences' active insiders?

IDEAYA Biosciences' insider roster includes Michael Dillon (SVP), Yujiro Hata (President, CEO & Director), Andres Ruiz Briseno (Senior Vice President, Head of Finance and Investor Relations), Paul Stone (CFO), and Jason Throne (insider). Learn More on IDEAYA Biosciences' active insiders.

Are insiders buying or selling shares of IDEAYA Biosciences?

In the last twelve months, insiders at the sold shares 11 times. They sold a total of 301,201 shares worth more than $11,863,540.29. The most recent insider tranaction occured on May, 29th when insider Michael Anthony White sold 28,500 shares worth more than $1,032,840.00. Insiders at IDEAYA Biosciences own 3.5% of the company. Learn More about insider trades at IDEAYA Biosciences.

Information on this page was last updated on 5/29/2024.

Jason Throne Insider Trading History at IDEAYA Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2023Sell5,163$30.09$155,354.67View SEC Filing Icon  
9/12/2023Sell1,000$30.00$30,000.00View SEC Filing Icon  
9/5/2023Sell1,737$30.03$52,162.11View SEC Filing Icon  
9/1/2023Sell2,100$30.03$63,063.0032,531View SEC Filing Icon  
8/9/2023Sell5,000$25.09$125,450.00View SEC Filing Icon  
7/10/2023Sell9,485$23.00$218,155.00View SEC Filing Icon  
5/31/2023Sell432$23.00$9,936.00View SEC Filing Icon  
5/22/2023Sell500$23.00$11,500.00View SEC Filing Icon  
12/4/2020Sell1,979$15.37$30,417.23View SEC Filing Icon  
6/4/2020Sell2,205$8.66$19,095.30View SEC Filing Icon  
See Full Table

Jason Throne Buying and Selling Activity at IDEAYA Biosciences

This chart shows Jason Throne's buying and selling at IDEAYA Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IDEAYA Biosciences Company Overview

IDEAYA Biosciences logo
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $25.35
Low: $25.20
High: $25.91

50 Day Range

MA: $30.79
Low: $25.54
High: $37.46

2 Week Range

Now: $25.35
Low: $25.20
High: $47.74

Volume

60,643 shs

Average Volume

845,788 shs

Market Capitalization

$2.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86